Pluri Inc 's

Cellav operates in the markets for aesthetics, wellness, and longevity products, including skincare, consumer health, biotechnology, and regenerative products. The company competes with established and emerging firms developing products based on exosomes, cell-derived ingredients, plant-derived ingredients, conditioned media, and bioactive formulations. Key competitive factors include product performance, scientific support, quality and safety, regulatory compliance, manufacturing capabilities, distribution, brand recognition, customer experience, and pricing. Competitors often possess greater financial, commercial, manufacturing, research and development, regulatory, and marketing resources, including direct-to-consumer brands and providers. The markets are global, with significant activity in North America, Europe, and Asia, involving multinational consumer-products, pharmaceutical, biotechnology, and medical-aesthetics companies. In the cell therapy contract development and manufacturing organization (CDMO) sector, Cellav competes with companies such as Lonza Group AG, AGC Biologics A/S, and Charles River Laboratories International, Inc. These competitors are large service providers offering multiple technologies and dosage form capabilities. Competition in the CDMO sector is influenced by geographic location, technological capabilities, operational capacity, manufacturing expertise, and pricing. Some competitors also provide advanced manufacturing efficiency and capabilities for late-stage cell therapy clinical trials. Other competitors named in filings include Aleph Farms, Ark Biotech, Ayana Bio LLC, Believer Meats, California Cultured, Inc., Coffeesai, DSM Firmenich AG, Esco Aster, Future Meat, GEA, Gelatex, Givaudan International SA, GOOD Meat, Gourmey, Kokomodo, Mosa Meat, Pluri Biotech, Plurinuva, Tnuva, and Upside Foods.